 | • レポートコード：MRC2312MG15949 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のヒト血漿分画製品市場規模と予測を収録しています。・世界のヒト血漿分画製品市場：売上、2018年-2023年、2024年-2029年 ・世界のヒト血漿分画製品市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のヒト血漿分画製品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「免疫グロブリン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 ヒト血漿分画製品のグローバル主要企業は、Takeda、 CSL、 Grifols、 Octapharma、 Kedrion、 LFB Group、 Biotest、 BPL、 RAAS、 CBPO、 Hualan Bio、 Tiantan Bio、 Shuanglin Bio、 Boya Bio、 Yuanda Shuyang、 Weiguang Bio、 Nanyue Bio、 KM Biologicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、ヒト血漿分画製品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のヒト血漿分画製品市場：タイプ別、2018年-2023年、2024年-2029年 世界のヒト血漿分画製品市場：タイプ別市場シェア、2022年 ・免疫グロブリン、凝固因子、アルブミン、その他 世界のヒト血漿分画製品市場：用途別、2018年-2023年、2024年-2029年 世界のヒト血漿分画製品市場：用途別市場シェア、2022年 ・病院、小売薬局、その他 世界のヒト血漿分画製品市場：地域・国別、2018年-2023年、2024年-2029年 世界のヒト血漿分画製品市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるヒト血漿分画製品のグローバル売上、2018年-2023年 ・主要企業におけるヒト血漿分画製品のグローバル売上シェア、2022年 ・主要企業におけるヒト血漿分画製品のグローバル販売量、2018年-2023年 ・主要企業におけるヒト血漿分画製品のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Takeda、 CSL、 Grifols、 Octapharma、 Kedrion、 LFB Group、 Biotest、 BPL、 RAAS、 CBPO、 Hualan Bio、 Tiantan Bio、 Shuanglin Bio、 Boya Bio、 Yuanda Shuyang、 Weiguang Bio、 Nanyue Bio、 KM Biologics ************************************************************* ・調査・分析レポートの概要 ヒト血漿分画製品市場の定義 市場セグメント 世界のヒト血漿分画製品市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のヒト血漿分画製品市場規模 世界のヒト血漿分画製品市場規模：2022年 VS 2029年 世界のヒト血漿分画製品市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのヒト血漿分画製品の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のヒト血漿分画製品製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：免疫グロブリン、凝固因子、アルブミン、その他 ヒト血漿分画製品のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、小売薬局、その他 ヒト血漿分画製品の用途別グローバル売上・予測 ・地域別市場分析 地域別ヒト血漿分画製品市場規模 2022年と2029年 地域別ヒト血漿分画製品売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Takeda、 CSL、 Grifols、 Octapharma、 Kedrion、 LFB Group、 Biotest、 BPL、 RAAS、 CBPO、 Hualan Bio、 Tiantan Bio、 Shuanglin Bio、 Boya Bio、 Yuanda Shuyang、 Weiguang Bio、 Nanyue Bio、 KM Biologics ... |
This research report provides a comprehensive analysis of the Human Plasma Fractionation Product market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Human Plasma Fractionation Product market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Human Plasma Fractionation Product, challenges faced by the industry, and potential opportunities for market players.
The global Human Plasma Fractionation Product market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Human Plasma Fractionation Product market presents opportunities for various stakeholders, including Hospital, Retail Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Human Plasma Fractionation Product market. Additionally, the growing consumer demand present avenues for market expansion.
The global Human Plasma Fractionation Product market was valued at US$ 28610 million in 2022 and is projected to reach US$ 48950 million by 2029, at a CAGR of 8.0% during the forecast period.
The Human Plasma Fractionation Product Market is driven by the increasing demand for plasma-derived therapies and the rising prevalence of various diseases. These products, including clotting factors and immunoglobulins, are crucial for treating rare and life-threatening conditions. However, a significant challenge is the need for a stable supply of plasma donations and the complex fractionation processes required to manufacture these products. Ensuring the safety and quality of plasma-derived therapies through strict regulatory compliance is another challenge for manufacturers. Additionally, market competition and pricing pressures pose challenges, necessitating a balance between affordability and sustaining the supply chain to meet the healthcare demands while maintaining the highest standards of patient care.
Key Features:
The research report on the Human Plasma Fractionation Product market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Human Plasma Fractionation Product market.
Market Overview: The report provides a comprehensive overview of the Human Plasma Fractionation Product market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Immune Globulin, Coagulation Factor), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Human Plasma Fractionation Product market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Human Plasma Fractionation Product market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Human Plasma Fractionation Product market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Human Plasma Fractionation Product market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Human Plasma Fractionation Product market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Human Plasma Fractionation Product market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Human Plasma Fractionation Product, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Human Plasma Fractionation Product market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Human Plasma Fractionation Product market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Market segment by Application
Hospital
Retail Pharmacy
Other
Global Human Plasma Fractionation Product Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Plasma Fractionation Product, market overview.
Chapter 2: Global Human Plasma Fractionation Product market size in revenue.
Chapter 3: Detailed analysis of Human Plasma Fractionation Product company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Plasma Fractionation Product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Human Plasma Fractionation Product Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Plasma Fractionation Product Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Human Plasma Fractionation Product Overall Market Size
2.1 Global Human Plasma Fractionation Product Market Size: 2022 VS 2029
2.2 Global Human Plasma Fractionation Product Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Human Plasma Fractionation Product Players in Global Market
3.2 Top Global Human Plasma Fractionation Product Companies Ranked by Revenue
3.3 Global Human Plasma Fractionation Product Revenue by Companies
3.4 Top 3 and Top 5 Human Plasma Fractionation Product Companies in Global Market, by Revenue in 2022
3.5 Global Companies Human Plasma Fractionation Product Product Type
3.6 Tier 1, Tier 2 and Tier 3 Human Plasma Fractionation Product Players in Global Market
3.6.1 List of Global Tier 1 Human Plasma Fractionation Product Companies
3.6.2 List of Global Tier 2 and Tier 3 Human Plasma Fractionation Product Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Human Plasma Fractionation Product Market Size Markets, 2022 & 2029
4.1.2 Immune Globulin
4.1.3 Coagulation Factor
4.1.4 Albumin
4.1.5 Other
4.2 By Type – Global Human Plasma Fractionation Product Revenue & Forecasts
4.2.1 By Type – Global Human Plasma Fractionation Product Revenue, 2018-2023
4.2.2 By Type – Global Human Plasma Fractionation Product Revenue, 2024-2029
4.2.3 By Type – Global Human Plasma Fractionation Product Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Human Plasma Fractionation Product Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Human Plasma Fractionation Product Revenue & Forecasts
5.2.1 By Application – Global Human Plasma Fractionation Product Revenue, 2018-2023
5.2.2 By Application – Global Human Plasma Fractionation Product Revenue, 2024-2029
5.2.3 By Application – Global Human Plasma Fractionation Product Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Human Plasma Fractionation Product Market Size, 2022 & 2029
6.2 By Region – Global Human Plasma Fractionation Product Revenue & Forecasts
6.2.1 By Region – Global Human Plasma Fractionation Product Revenue, 2018-2023
6.2.2 By Region – Global Human Plasma Fractionation Product Revenue, 2024-2029
6.2.3 By Region – Global Human Plasma Fractionation Product Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Human Plasma Fractionation Product Revenue, 2018-2029
6.3.2 US Human Plasma Fractionation Product Market Size, 2018-2029
6.3.3 Canada Human Plasma Fractionation Product Market Size, 2018-2029
6.3.4 Mexico Human Plasma Fractionation Product Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Human Plasma Fractionation Product Revenue, 2018-2029
6.4.2 Germany Human Plasma Fractionation Product Market Size, 2018-2029
6.4.3 France Human Plasma Fractionation Product Market Size, 2018-2029
6.4.4 U.K. Human Plasma Fractionation Product Market Size, 2018-2029
6.4.5 Italy Human Plasma Fractionation Product Market Size, 2018-2029
6.4.6 Russia Human Plasma Fractionation Product Market Size, 2018-2029
6.4.7 Nordic Countries Human Plasma Fractionation Product Market Size, 2018-2029
6.4.8 Benelux Human Plasma Fractionation Product Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Human Plasma Fractionation Product Revenue, 2018-2029
6.5.2 China Human Plasma Fractionation Product Market Size, 2018-2029
6.5.3 Japan Human Plasma Fractionation Product Market Size, 2018-2029
6.5.4 South Korea Human Plasma Fractionation Product Market Size, 2018-2029
6.5.5 Southeast Asia Human Plasma Fractionation Product Market Size, 2018-2029
6.5.6 India Human Plasma Fractionation Product Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Human Plasma Fractionation Product Revenue, 2018-2029
6.6.2 Brazil Human Plasma Fractionation Product Market Size, 2018-2029
6.6.3 Argentina Human Plasma Fractionation Product Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Human Plasma Fractionation Product Revenue, 2018-2029
6.7.2 Turkey Human Plasma Fractionation Product Market Size, 2018-2029
6.7.3 Israel Human Plasma Fractionation Product Market Size, 2018-2029
6.7.4 Saudi Arabia Human Plasma Fractionation Product Market Size, 2018-2029
6.7.5 UAE Human Plasma Fractionation Product Market Size, 2018-2029
7 Human Plasma Fractionation Product Companies Profiles
7.1 Takeda
7.1.1 Takeda Company Summary
7.1.2 Takeda Business Overview
7.1.3 Takeda Human Plasma Fractionation Product Major Product Offerings
7.1.4 Takeda Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.1.5 Takeda Key News & Latest Developments
7.2 CSL
7.2.1 CSL Company Summary
7.2.2 CSL Business Overview
7.2.3 CSL Human Plasma Fractionation Product Major Product Offerings
7.2.4 CSL Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.2.5 CSL Key News & Latest Developments
7.3 Grifols
7.3.1 Grifols Company Summary
7.3.2 Grifols Business Overview
7.3.3 Grifols Human Plasma Fractionation Product Major Product Offerings
7.3.4 Grifols Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.3.5 Grifols Key News & Latest Developments
7.4 Octapharma
7.4.1 Octapharma Company Summary
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Human Plasma Fractionation Product Major Product Offerings
7.4.4 Octapharma Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.4.5 Octapharma Key News & Latest Developments
7.5 Kedrion
7.5.1 Kedrion Company Summary
7.5.2 Kedrion Business Overview
7.5.3 Kedrion Human Plasma Fractionation Product Major Product Offerings
7.5.4 Kedrion Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.5.5 Kedrion Key News & Latest Developments
7.6 LFB Group
7.6.1 LFB Group Company Summary
7.6.2 LFB Group Business Overview
7.6.3 LFB Group Human Plasma Fractionation Product Major Product Offerings
7.6.4 LFB Group Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.6.5 LFB Group Key News & Latest Developments
7.7 Biotest
7.7.1 Biotest Company Summary
7.7.2 Biotest Business Overview
7.7.3 Biotest Human Plasma Fractionation Product Major Product Offerings
7.7.4 Biotest Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.7.5 Biotest Key News & Latest Developments
7.8 BPL
7.8.1 BPL Company Summary
7.8.2 BPL Business Overview
7.8.3 BPL Human Plasma Fractionation Product Major Product Offerings
7.8.4 BPL Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.8.5 BPL Key News & Latest Developments
7.9 RAAS
7.9.1 RAAS Company Summary
7.9.2 RAAS Business Overview
7.9.3 RAAS Human Plasma Fractionation Product Major Product Offerings
7.9.4 RAAS Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.9.5 RAAS Key News & Latest Developments
7.10 CBPO
7.10.1 CBPO Company Summary
7.10.2 CBPO Business Overview
7.10.3 CBPO Human Plasma Fractionation Product Major Product Offerings
7.10.4 CBPO Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.10.5 CBPO Key News & Latest Developments
7.11 Hualan Bio
7.11.1 Hualan Bio Company Summary
7.11.2 Hualan Bio Business Overview
7.11.3 Hualan Bio Human Plasma Fractionation Product Major Product Offerings
7.11.4 Hualan Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.11.5 Hualan Bio Key News & Latest Developments
7.12 Tiantan Bio
7.12.1 Tiantan Bio Company Summary
7.12.2 Tiantan Bio Business Overview
7.12.3 Tiantan Bio Human Plasma Fractionation Product Major Product Offerings
7.12.4 Tiantan Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.12.5 Tiantan Bio Key News & Latest Developments
7.13 Shuanglin Bio
7.13.1 Shuanglin Bio Company Summary
7.13.2 Shuanglin Bio Business Overview
7.13.3 Shuanglin Bio Human Plasma Fractionation Product Major Product Offerings
7.13.4 Shuanglin Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.13.5 Shuanglin Bio Key News & Latest Developments
7.14 Boya Bio
7.14.1 Boya Bio Company Summary
7.14.2 Boya Bio Business Overview
7.14.3 Boya Bio Human Plasma Fractionation Product Major Product Offerings
7.14.4 Boya Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.14.5 Boya Bio Key News & Latest Developments
7.15 Yuanda Shuyang
7.15.1 Yuanda Shuyang Company Summary
7.15.2 Yuanda Shuyang Business Overview
7.15.3 Yuanda Shuyang Human Plasma Fractionation Product Major Product Offerings
7.15.4 Yuanda Shuyang Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.15.5 Yuanda Shuyang Key News & Latest Developments
7.16 Weiguang Bio
7.16.1 Weiguang Bio Company Summary
7.16.2 Weiguang Bio Business Overview
7.16.3 Weiguang Bio Human Plasma Fractionation Product Major Product Offerings
7.16.4 Weiguang Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.16.5 Weiguang Bio Key News & Latest Developments
7.17 Nanyue Bio
7.17.1 Nanyue Bio Company Summary
7.17.2 Nanyue Bio Business Overview
7.17.3 Nanyue Bio Human Plasma Fractionation Product Major Product Offerings
7.17.4 Nanyue Bio Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.17.5 Nanyue Bio Key News & Latest Developments
7.18 KM Biologics
7.18.1 KM Biologics Company Summary
7.18.2 KM Biologics Business Overview
7.18.3 KM Biologics Human Plasma Fractionation Product Major Product Offerings
7.18.4 KM Biologics Human Plasma Fractionation Product Revenue in Global Market (2018-2023)
7.18.5 KM Biologics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer